Lusaris Therapeutics Launches with $60 Million Series A Financing to Redefine the Treatment of Severe Neuropsychiatric and ...
Lead Program LSR-1019 is a Proprietary Sublingual Formulation of 5-MeO-DMT, a Potent, Fast-Acting and Rapidly Clearing Psychedelic, in Development for Treatment-Resistant Depression and Other Neuropsychiatric Indications RA Capital Management Incubated the …